Structure Therapeutics (GPCR) Competitors $24.32 -0.13 (-0.55%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. MENS, ACLX, PCVX, KRYS, ARWR, ACAD, ADMA, AAPG, MTSR, and MIRMShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Metsera (MTSR), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Jyong Biotech Arcellx Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera Mirum Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is GPCR or MENS more profitable? Jyong Biotech's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Jyong Biotech N/A N/A N/A Do analysts recommend GPCR or MENS? Structure Therapeutics currently has a consensus target price of $68.67, indicating a potential upside of 182.35%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of GPCR or MENS? 91.8% of Structure Therapeutics shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to GPCR or MENS? In the previous week, Jyong Biotech had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 9 mentions for Jyong Biotech and 6 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.94 beat Jyong Biotech's score of 0.53 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, GPCR or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-23.16Jyong BiotechN/AN/AN/AN/AN/A SummaryStructure Therapeutics beats Jyong Biotech on 7 of the 10 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$3.15B$5.76B$10.50BDividend YieldN/A2.36%5.61%4.58%P/E Ratio-23.1421.0376.6326.90Price / SalesN/A451.34551.24127.98Price / CashN/A44.8325.8131.15Price / Book1.619.8413.666.52Net Income-$122.53M-$52.73M$3.29B$271.58M7 Day Performance11.61%3.65%2.40%3.67%1 Month Performance24.02%5.95%4.81%8.14%1 Year Performance-42.57%17.38%81.05%26.94% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics3.3082 of 5 stars$24.32-0.5%$68.67+182.3%-41.7%$1.40BN/A-23.14136MENSJyong BiotechN/A$51.82-15.7%N/AN/A$4.68BN/A0.0031Gap DownHigh Trading VolumeACLXArcellx2.3311 of 5 stars$75.20-1.3%$114.31+52.0%-9.7%$4.23B$107.94M-21.9980Positive NewsPCVXVaxcyte2.0942 of 5 stars$31.00-3.6%$106.25+242.7%-70.9%$4.18BN/A-7.54160Positive NewsKRYSKrystal Biotech4.9409 of 5 stars$155.71+8.4%$209.00+34.2%-10.2%$4.16B$359.21M31.65210High Trading VolumeARWRArrowhead Pharmaceuticals4.2239 of 5 stars$28.67-3.5%$43.14+50.5%+54.1%$4.11B$3.55M-22.40400ACADACADIA Pharmaceuticals4.2658 of 5 stars$24.67+4.5%$29.65+20.2%+48.4%$3.98B$957.80M18.55510Positive NewsADMAADMA Biologics3.3378 of 5 stars$15.30-5.0%$27.67+80.8%-19.8%$3.84B$426.45M17.79530Positive NewsAAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.77B$134.35M0.00600MTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.75BN/A0.0081Trending NewsAnalyst DowngradeMIRMMirum Pharmaceuticals3.3931 of 5 stars$74.19-0.2%$74.44+0.3%+89.8%$3.73B$336.89M-61.31140 Related Companies and Tools Related Companies Jyong Biotech Alternatives Arcellx Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Arrowhead Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives ADMA Biologics Alternatives Ascentage Pharma Group International Alternatives Metsera Alternatives Mirum Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts